Field Medical develops the FieldForce™ Ablation System, a next-generation pulsed field ablation (PFA) platform designed for transmural lesion creation and targeted ventricular tachycardia (VT) ablation. The system pairs breakthrough catheter design with proprietary FieldBending™ energy to enable rapid, targeted ablation. The device is investigational and limited to investigational use under U.S. law. The company plans to use new funding to initiate its pivotal VERITAS trial and to advance FieldForce development while expanding clinical and regulatory capabilities. Field Medical received Breakthrough Device Designation in 2024 and was selected for the FDA TAP Pilot Program for its VT indication. With strong pilot data presented at Heart Rhythm 2025, the company is positioning to address an underpenetrated VT market. Field Medical is developing next-generation pulsed field ablation (PFA) technologies, centered on the FieldForce™ Ablation System and its built-for-purpose, contact-force focal PFA catheter. The system enables an instantaneous ablation workflow with therapy delivered in a fraction of a second and is powered by the company's proprietary FieldBending™ technology that delivers brief, high-intensity electric fields. Field Medical positions the System as a single advanced solution for a full spectrum of cardiac arrhythmias, including ventricular tachycardia (VT) and atrial fibrillation (AF). The company is completing two pilot studies (VCAS for VT and Field PULSE for AF) and advancing toward VERITAS, a planned pivotal trial focused on VT. Financially, Field Medical closed a $40 million Series A that includes $20 million in new capital and the conversion of $20 million in seed-round debt to support clinical programs, commercial development, and operational scale-up. Founded in 2022, the company received FDA Breakthrough Device Designation and was included in the TAP Pilot Program in 2024. Field Medical, Inc. is described as an emerging leader in cardiac catheter ablation and is based in Cardiff-by-the-Sea, California. The company operates in the cardiac catheter ablation space. Field Medical closed an oversubscribed seed round totaling $14M. The financing was structured as convertible notes. The seed was led by private investors and included multiple strategic investors. The article did not disclose revenue, user metrics, prior rounds, founding year, or additional financial terms.

Total raised

$89M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2025